<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Lymph node involvement by histopathology informs <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> prognosis, whereas recurrence in 25% of node-negative patients suggests the presence of occult <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>GUCY2C (guanylyl cyclase C) is a marker of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells that identifies occult nodal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> associated with recurrence risk </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we defined the association of occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, quantified by GUCY2C reverse transcriptase-PCR (RT-PCR), with outcomes in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>EXPERIMENTAL DESIGN: Lymph nodes (range: 2-159) from 291 prospectively enrolled node-negative <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients were analyzed by histopathology and GUCY2C quantitative RT-PCR </plain></SENT>
<SENT sid="4" pm="."><plain>Participants were followed for a median of 24 months (range: 2-63) </plain></SENT>
<SENT sid="5" pm="."><plain>Time to recurrence and disease-free survival served as primary and secondary outcomes, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Association of outcomes with prognostic markers, including molecular <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden, was estimated by recursive partitioning and Cox models </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: In this cohort, 176 (60%) patients exhibited low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (Mol(Low)), and <z:hpo ids='HP_0000001'>all</z:hpo> but four remained free of disease [recurrence rate 2.3% (95% CI, 0.1-4.5%)] </plain></SENT>
<SENT sid="8" pm="."><plain>Also, 90 (31%) patients exhibited intermediate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (Mol(Int)) and 30 [33.3% (23.7-44.1)] developed <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>Furthermore, 25 (9%) patients exhibited high <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (Mol(High)) and 17 [68.0% (46.5-85.1)] developed <z:e sem="disease" ids="C0277556" disease_type="Disease or Syndrome" abbrv="">recurrent disease</z:e> (P &lt; 0.001) </plain></SENT>
<SENT sid="10" pm="."><plain>Occult <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden was an independent marker of prognosis </plain></SENT>
<SENT sid="11" pm="."><plain>Mol(Int) and Mol(High) patients exhibited a graded risk of earlier time to recurrence [Mol(Int), adjusted HR 25.52 (11.08-143.18); P &lt; 0.001; Mol(High), 65.38 (39.01-676.94); P &lt; 0.001] and reduced disease-free survival [Mol(Int), 9.77 (6.26-87.26); P &lt; 0.001; Mol(High), 22.97 (21.59-316.16); P &lt; 0.001] </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSION: Molecular <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden in lymph nodes is independently associated with time to recurrence and disease-free survival in patients with node-negative <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>